Marpai, Inc.
Key Highlights
- Modernizing the Third-Party Administrator (TPA) industry through tech-driven health benefit management.
- Significant reduction in net losses compared to the previous fiscal year.
- Core business model focused on recurring monthly fees from self-insured employers.
Financial Analysis
Marpai, Inc. Annual Report: A Plain-English Guide
I’ve put together this guide to help you understand Marpai, Inc.’s performance. Instead of digging through dense legal filings, we’ll break down the business so you can decide if it fits your portfolio.
1. The Big Picture
Think of Marpai as the "engine room" for companies that pay for their own employee health benefits. Instead of using a giant insurance company, these employers pay for their own claims. They hire Marpai to handle the heavy lifting: processing claims, managing pharmacy benefits, and helping employees navigate care.
Marpai aims to modernize this old-school industry using tech and data. They act as a Third-Party Administrator (TPA), making money by charging employers a monthly fee for every employee they manage.
2. The Numbers (2025 Snapshot)
Marpai is in a difficult financial spot. Here is the reality of their 2025 performance:
- Revenue: The company brought in $18.4 million.
- Profit: They lost $16.6 million. While this is better than their $22.1 million loss in 2024, they are still spending far more than they earn.
- Cash on Hand: They have only $133,000 in cash. This isn't enough to cover even one month of expenses.
- Debt: They owe $28.2 million, much of which comes with high interest rates.
- The "Going Concern" Warning: Auditors have officially flagged "substantial doubt" about the company’s ability to stay in business over the next year.
3. Wins and Challenges
- The Challenge: About 28% of their customers left in 2025. It costs between $15,000 and $25,000 to sign a new mid-sized employer. Losing nearly a third of their clients makes it very hard to become profitable.
- The Competition: Marpai fights an uphill battle against nearly 1,000 competitors, including giants like Aetna and Cigna. These companies have massive resources and better discounts. If an employer gets frustrated with Marpai, they can easily switch back to a traditional insurance plan.
4. Financial Health
Simply put, the company is burning cash. They had a negative cash flow of $7.5 million this year. They need to raise more money to keep the lights on. This likely means they will issue more shares, which reduces your ownership percentage and lowers the value of your current stake. They need to raise $10 million to $15 million just to fund operations through 2026.
5. The Risks
- Survival Risk: Without an immediate cash injection or a merger, the company faces a high risk of going out of business.
- Client Concentration: Their two largest clients provide 10% of their revenue. Losing a big client hurts their bottom line significantly.
- Legal & Regulatory: They face strict state-by-state rules. Any mistake, such as a data breach or failure to follow federal health laws, could lead to losing their licenses and shutting down.
6. The Verdict
Marpai is struggling to prove it can survive. While their tech-focused approach is interesting, the high customer turnover and urgent need for cash make this a very high-risk investment. View this as a "distressed" stock. The primary risk is a total loss of your investment if the company is forced into bankruptcy.
Final Thought for Investors: Before considering a position, ask yourself if you are comfortable with the high probability of share dilution or the risk of insolvency. This is a speculative play that requires monitoring the company's ability to secure new funding in the coming months.
Risk Factors
- Substantial doubt regarding the company's ability to continue as a going concern due to liquidity issues.
- High customer churn rate of 28% in 2025, threatening long-term revenue stability.
- Severe capital constraints with only $133,000 in cash against $28.2 million in debt.
- High probability of shareholder dilution as the company seeks $10M-$15M in emergency funding.
Why This Matters
Stockadora surfaced this report because Marpai is at a critical inflection point where survival is no longer guaranteed. With auditors flagging 'substantial doubt' and a massive cash crunch looming, this company represents a high-risk, high-stakes scenario for investors.
We believe this report is essential reading for those tracking the intersection of health-tech and distressed assets. It serves as a cautionary tale on the difficulties of disrupting the entrenched insurance industry while burning through capital.
Financial Metrics
Learn More
About This Analysis
AI-powered summary derived from the original SEC filing.
Document Information
SEC Filing
View Original DocumentAnalysis Processed
March 26, 2026 at 09:18 AM
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.